Effect of galcanezumab on possible menstrual-related migraine: exploratory analyses results from EVOLVE-1, EVOLVE-2 and REGAIN

被引：0
|
作者：
Fernandes, Maria S. [1 ]
Detke, Holland C. [1 ]
Zhang, Qi [1 ]
Pavlovic, Jelena M. [2 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10461 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O33
引用
收藏
页数：2
相关论文
共 34 条
  • [1] EFFECT OF GALCANEZUMAB ON POSSIBLE MENSTRUAL-RELATED MIGRAINE: EXPLORATORY ANALYSES RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN
    Fernandes, M. F. S.
    Detke, H. C.
    Zhang, Q.
    Pavlovic, J. M.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 97 - 98
  • [2] Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Dell'Agnello, Grazia
    Tockhorn-Heidenreich, Antje
    Zhang, Qi
    Ruff, Dustin D.
    Pearlman, Eric M.
    Aurora, Sheena K.
    Ford, Janet H.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [3] Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2
    Zhang, Qi
    Morrow, Paula A.
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [4] Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies
    Zhang, Q.
    Ruff, D.
    Pearlman, E.
    Govindan, S.
    Aurora, S.
    HEADACHE, 2018, 58 : 165 - 166
  • [5] EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 51 - 52
  • [6] Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [7] Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2
    Macgregor, E. Anne
    Okonkwo, Rose
    Detke, Holland C.
    Polavieja, Pepa
    Fernandes, Maria S.
    Pavlovic, Jelena M.
    HEADACHE, 2024, 64 (02): : 179 - 187
  • [8] Benefit-Risk Assessment of Galcanezumab versus Placebo for the Treatment of Episodic and Chronic Migraine: Results from EVOLVE-1, EVOLVE-2, and REGAIN Clinical Trials
    Ruff, Dustin D.
    Tockhorn-Heidenreich, Antje
    Foster, Shonda A.
    Nichols, Russell M.
    Stauffer, Virginia L.
    CEPHALALGIA, 2019, 39 : 219 - 220
  • [9] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [10] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 339 - 340
1234